Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

By P. Fong, T. Yap, D. Boss, C. Carden, M. Mergui-Roelvink, C. Gourley, J. De Grève, J. Lubiński, S. Shanley, Christina Messiou and 8 more. Journal of Clinical Oncology, 2010

991 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/19df5ac9381cefb411f6303ab69f24d6f8d02980

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Lord
2. Alan Ashworth
3. Mark J. O'Connor

In Oncology

1. C. Lord
2. Alan Ashworth
3. Mark J. O'Connor

In Reproductive Medicine

1. Alan Ashworth
2. C. Lord

Citations in the corpus

• A decade of clinical development of PARP inhibitors in perspective (2019, background): “There is a clear association between the platinum-sensitivity, defined based on the time gap from last platinum exposure to disease progression, and response to PARPi [20].”
• PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance (2020, background): “, 2013), Olaparib (46%) (Fong et al., 2010), and Talazoparib (42%) (de Bono et al.”
• Cancer genomics: from discovery science to personalized medicine (2011, background): “For example, BRCA loss-of-function mutations can markedly enhance the response to a poly(ADP) ribose polymerase 1 (PARP1) inhibitor in patients with breast and ovarian cancer”
• Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation (2014, background): “In addition, data are limited in germline BRCA1/2 mutation carriers with platinum-resistant ovarian cancer and chemotherapy-refractory breast cancer.(11) Here, we JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 33 NUMBER 3 JANUARY 20 2015”
• PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017, background): “Consistent with the HRR defect, tumors with BRCAness might also share therapeutic vulnerabilities with gBRCAm tumors, such as platinum salt sensitivity (36).”